Investigating the AZDR1208 resistance in HSB-2 cells

The study uses RNA sequencing to profile AZD1208 resistant (AZDR) vs AZD1208 sensitive HSB-2 cells. PIM inhibitor treatment decreases leukemia burden in early T-cell precursor acute lymphoblastic leukemias (ETP-ALL) both in vitro and in vivo. However, prolonged treatment of ETP-ALL with PIM kinase inhibitors results in PIM inhibitor resistance. The analysis revealed that the HOXA9, mTOR, MYC, NF-?B, and PI3K-AKT pathways were activated in PIM inhibitor resistant ETP-ALL Overall design: PIM inhibitor resistance in HSB-2 cells was induced by growing the cells in the presence of increasing doses of AZD1208 over a 4 month period until resulting cell populations were able to maintain their growth at 1 µM AZD1208. RNA sequencing was utilized to define differentially expressed genes.